1887

Chapter 11 : Future Trends in Control of Neglected Tropical Diseases and the Antipoverty Vaccines

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $7.00

Preview this chapter:
Zoom in
Zoomout

Future Trends in Control of Neglected Tropical Diseases and the Antipoverty Vaccines, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818753/9781555818746_Chap11-1.gif /docserver/preview/fulltext/10.1128/9781555818753/9781555818746_Chap11-2.gif

Abstract:

With an ambitious global agenda to scale up integrated interventions for more than 1 billion people living in 56 developing countries where multiple neglected tropical diseases (NTDs) are coendemic, we need to carefully consider the specter of resistance and other forms of drug failure. Of the six possible different drugs contained in the rapid-impact package—azithromycin, praziquantel, albendazole or mebendazole, and diethylcarbamazine or ivermectin—the agents albendazole and mebendazole particularly stand out as drugs that could induce resistance. To create a truly robust pipeline of NTD drugs, we need to look to either small biopharmaceuticals or a new generation of NTD product development partnerships (PDPs). Many of the NTD PDPs are funded in part by the Bill & Melinda Gates Foundation. With genomes completed for a large number of NTD pathogens, including the agents that cause Chagas disease, human African trypanosomiasis, leishmaniasis, leprosy, leptospirosis, lymphatic filariasis (LF), schistosomiasis, and trachoma, it should be theoretically possible to mine bioinformatics databases in order develop a large number of antipoverty vaccines in the coming decade. The global control and elimination of the NTDs will require mechanisms to introduce new health products, e.g., vaccines, drugs, and diagnostics, together with existing drugs, in order to create new-generation rapid-impact packages. This approach will be necessary for sustainably reducing poverty and for meeting Millennium Development Goal targets.

Citation: Hotez P. 2013. Future Trends in Control of Neglected Tropical Diseases and the Antipoverty Vaccines, p 213-230. In Forgotten People Forgotten Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555818753.ch11

Key Concept Ranking

Human African Trypanosomiasis
0.49295616
Hepatitis B Vaccine
0.46459806
Human Papillomavirus Vaccine
0.4591322
0.49295616
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555818753.chap11
1. Albonico M ,, Bickle Q ,, Ramsan M ,, Montresor A ,, Savioli L ,, Taylor M . 2003. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ 81:343352.
2. Albonico M ,, Engels D ,, Savioli L . 2004a. Monitoring drug efficacy and early detection of drug resistance in human soil-transmitted nematodes: a pressing public health agenda for helminth control. Int J Parasitol 34:12051210.
3. Albonico M ,, Montresor A ,, Crompton DW ,, Savioli L . 2006. Intervention for the control of soil-transmitted helminthiasis in the community. Adv Parasitol 61:311348.
4. Albonico M ,, Wright V ,, Bickle O . 2004b. Molecular analysis of the β-tubulin gene of human hookworms as a basis for possible benzimidazole resistance on Pemba Island. Mol Biochem Parasitol 134:281284.
5. Anderson RM . 1999. The pandemic of antibiotic resistance. Nat Med 5:147149.
6. Austin DJ ,, Kakehashi M ,, Anderson RM . 1997. The transmission dynamics of antibiotic-resistance bacteria: the relationship between resistance in commensal organisms and antibiotic consumption. Proc Biol Sci 264:16291638.
7. Bennet A ,, Guyatt H . 2000. Reducing intestinal nematode infection: efficacy of albendazole and mebendazole. Parasitol Today 2:7174.
8. Bockarie MJ ,, Deb RM . 2010. Elimination of lymphatic filariasis: do we have the drugs to complete the job? Curr Opin Infect Dis 23:617620.
9. Bottazzi ME ,, Brown AS . 2008. Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm. Expert Rev Vaccines 7:14811492.
10. Chirac P ,, Torreele E . 2006. Global framework on essential health R&D. Lancet 367:15601561.
11. Conder GA ,, Campbell WC . 1995. Chemotherapy of nematode infections of veterinary importance, with special reference to drug resistance. Adv Parasitol 35:184.
12. Croft SL ,, Barrett MP ,, Urbina JA . 2005. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 21:508512.
13. Croft SL ,, Seifert K ,, Yardley V . 2006. Current scenario of drug development for leishmaniasis. Indian J Med Res 123:399410.
14. Dumonteil E ,, Bottazzi ME ,, Zhan B ,, Heffernan MJ ,, Jones K ,, Valenzuela JG ,, Kamhawi S ,, Ortega J ,, Rosales SP ,, Lee BY ,, Bacon KM ,, Fleischer B ,, Slingsby B ,, Cravioto MB ,, Tapia-Conyer R ,, Hotez PJ . 2012. Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines 11:10431055.
15. Duthie MS ,, Gillis TP ,, Reed SG . 2011. Advances and hurdles on the way toward a leprosy vaccine. Hum Vaccin 7:11721183.
16. Duthie MS ,, Raman VS ,, Piazza FM ,, Reed SG . 2012. The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 30:134141.
17. Einarsdottir T ,, Huygen K . 2011. Buruli ulcer. Hum Vaccin 7:11981203.
18. El Sayed NM ,, Myler PJ ,, Blandin G ,, Berriman M ,, Crabtree J ,, Aggarwal G ,, Caler E ,, Renauld H ,, Worthey EA ,, Hertz-Fowler C ,, Ghedin E ,, Peacock C ,, Bartholomeu DC ,, Haas BJ ,, Tran AN ,, Wortman JR ,, Alsmark UC ,, Angiuoli S ,, Anupama A ,, Badger J ,, Bringaud F ,, Cadag E ,, Carlton JM ,, Cerqueira GC ,, Creasy T ,, Delcher AL ,, Djikeng A ,, Embley TM ,, Hauser C ,, Ivens AC ,, Kummerfeld SK ,, Pereira-Leal JB ,, Nilsson D ,, Peterson J ,, Salzberg SL ,, Shallom J ,, Silva JC ,, Sundaram J ,, Westenberger S ,, White O ,, Melville SE ,, Donelson JE ,, Andersson B ,, Stuart KD ,, Hall N . 2005. Comparative genomics of trypanosomatid parasitic protozoa. Science 309:404409.
19. Gallup JL ,, Sachs JD . 2001. The economic burden of malaria. Am J Trop Med Hyg 64 (1–2 Suppl): 8596.
20. Guy B ,, Barrere B ,, Malinowski C ,, Saville M ,, Teyssou R ,, Lang J . 2011. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29:72297241.
21. Harrison GA . 1978. Mosquitoes, Malaria, and Man: a History of the Hostilities since 1880. E.P. Dutton, New York, NY.
22. Hotez PJ . 2004. The National Institutes of Health roadmap and the developing world. J Investig Med 52:246247.
23. Hotez PJ . 2007. Control of onchocerciasis—the next generation. Lancet 369:19791980.
24. Hotez P . 2011a. A handful of “antipoverty” vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Aff (Millwood) 30:10801087.
25. Hotez PJ . 2011b. New antipoverty drugs, vaccines, and diagnostics: a research agenda for the US President's Global Health Initiative (GHI). PLoS Negl Trop Dis 5:e1133.
26. Hotez P . 2011c. Enlarging the “audacious goal”: elimination of the world's high prevalence neglected tropical diseases. Vaccine 29(Suppl 4): D104D110.
27. Hotez PJ ,, Bethony JM ,, Diemert DJ ,, Pearson M ,, Loukas A . 2010. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 8:814826.
28. Hotez PJ ,, Ferris MT . 2006. The antipoverty vaccines. Vaccine 24:57875799.
29. Hotez PJ ,, Molyneux DH ,, Fenwick A ,, Kumaresan J ,, Ehrlich Sachs S ,, Sachs JD ,, Savioli L . 2007. Control of neglected tropical diseases. N Engl J Med 357:10181027.
30. Keiser J ,, Utzinger J . 2008. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 299:19371948.
31. Ko AI ,, Goarant C ,, Picardeau M . 2009. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol 7:736747.
32. Kremer M ,, Glennerster R . 2004. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton University Press, Princeton, NJ.
33. Lee BY ,, Bacon KM ,, Bailey R ,, Wiringa AE ,, Smith KJ . 2011. The potential economic value of a hookworm vaccine. Vaccine 29:12011210.
34. Lee BY ,, Bacon KM ,, Wateska AR ,, Bottazzi ME ,, Dumonteil E ,, Hotez PJ . 2012. Modeling the economic value of a Chagas' disease therapeutic vaccine. Hum Vaccin Immunother 8:12931301.
35. Mackenzie CD ,, Geary TG . 2011. Flubenazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Rev Anti Infect Ther 9:497501.
36. Mahoney RT ,, Krattiger A ,, Clemens JD ,, Curtiss R III . 2007. The introduction of new vaccines into developing countries. IV. Global Access Strategies. Vaccine 25:40034011.
37. Mahoney RT ,, Maynard JE . 1999. The introduction of new vaccines into developing countries. Vaccine 17:646652.
38. Mathis AM ,, Holman JL ,, Sturk LM ,, Ismail MA ,, Boykin DW ,, Tidwell RR ,, Hall JE . 2006. Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrob Agents Chemother 50:21852191.
39. Moran M . 2005. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med 2:e302.
40. Moran M ,, Guzman J ,, Abela-Oversteegen L ,, Liyanage R ,, Omune B ,, Wu L ,, Chapman N ,, Gouglas D . 2011. Neglected Disease Research and Development: Is Innovation under Threat? G-finder Policy Cures, Sydney, Australia. http://policycures.org/downloads/g-finder_2011.pdf.
41. Morel CM ,, Acharya T ,, Broun D ,, Dangi A ,, Elias C ,, Ganguly NK ,, Gardner CA ,, Gupta RK ,, Haycock J ,, Heher AD ,, Hotez PJ ,, Kettler HE ,, Keusch GT ,, Krattiger AF ,, Kreutz FT ,, Lall S ,, Lee K ,, Mahoney R ,, Martinez-Palomo A ,, Mashelkar RA ,, Matlin SA ,, Mzimba M ,, Oehler J ,, Ridley RG ,, Senanayake P ,, Singer P ,, Yun M . 2005. Health innovation networks to help developing countries address neglected diseases. Science 309:401404.
42. Osei-Atweneboana MY ,, Eng JK ,, Boakye DA ,, Gyapoing JO ,, Prichard RK . 2007. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 369:20212029.
43. Prichard RK . 2007. Markers for benzimidazole resistance in human parasitic nematodes? Parasitology 134:19871992.
44. Quijano-Hernandez I ,, Dumonteil E . 2011. Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin 7:11841191.
45. Renslo AR ,, McKerrow JH . 2006. Drug discovery and development for neglected parasitic diseases. Nat Chem Biol 2:701710.
46. Riveau G ,, Deplanque D ,, Remoué F ,, Schacht AM ,, Vodougnon H ,, Capron M ,, Thiry M ,, Martial J ,, Libersa C ,, Capron A . 2012. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis 6:e1704.
47. Schwab AE ,, Boakye DA ,, Kyelem D ,, Prichard RK . 2005. Detection of benzimidazole resistance-associated mutations in the filarial nematode Wuchereria bancrofti and evidence for selection by albendazole and ivermectin combination treatment. Am J Trop Med Hyg 73:234238.
48. Schwab AE ,, Churcher TS ,, Schwab AJ ,, Basáñ ez MG ,, Prichard RK . 2007. An analysis of the population genetics of potential multi-drug resistance in Wuchereria bancrofti due to combination chemotherapy. Parasitology 134:10251040.
49. Tamarozzi F ,, Halliday A ,, Gentil K ,, Hoerauf A ,, Pearlman E ,, Taylor MJ . 2011. Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment. Clin Microbiol Rev 24:459468.
50. Tamarozzi F ,, Tendongfor N ,, Enyong PA ,, Esum M ,, Faragher B ,, Wanji S ,, Taylor MJ . 2012. Long term impact of large scale community-directed delivery of doxycycline for the treatment of onchocerciasis. Parasit Vectors 5:53.
51. Tavares NM ,, Silva RA ,, Costa DJ ,, Pitombo MA ,, Fukutani KF ,, Miranda JC ,, Valenzuela JG ,, Barral A ,, de Oliveira CI ,, Barral-Netto M ,, Brodskyn C . 2011. Lutzomyia longipalpis saliva or salivary protein LJM19 protects against Leishmania braziliensis and the saliva of its vector, Lutzomyia intermedia. PLoS Negl Trop Dis 5:e1169.
52. Tendler M ,, Simpson AJ . 2008. The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop 108:263266.
53. Vázquez-Chagoyán JC ,, Gupta S ,, Garg NJ . 2011. Vaccine development against Trypanosoma cruzi and Chagas disease. Adv Parasitol 75:121146.

Tables

Generic image for table
Table 11.1

New drugs developed between 1975 and 2004 specifically targeting NTDs

Modified from .

These drugs are not new chemical entities but rather a new salt, formulation, or combination.

Citation: Hotez P. 2013. Future Trends in Control of Neglected Tropical Diseases and the Antipoverty Vaccines, p 213-230. In Forgotten People Forgotten Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555818753.ch11
Generic image for table
Table 11.2

PDPs and related organizations for new drugs to treat human kinetoplastid infections

Citation: Hotez P. 2013. Future Trends in Control of Neglected Tropical Diseases and the Antipoverty Vaccines, p 213-230. In Forgotten People Forgotten Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555818753.ch11
Generic image for table
Table 11.3

PDPs for antipoverty vaccines to combat NTDs

Citation: Hotez P. 2013. Future Trends in Control of Neglected Tropical Diseases and the Antipoverty Vaccines, p 213-230. In Forgotten People Forgotten Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555818753.ch11

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error